NeuroPace stock has a bearish daily setup, despite a positive MACD histogram on the 15-minute chart.
NeuroPace stock has a bearish daily setup, despite a positive MACD histogram on the 15-minute chart. Price sits below all three daily exponential moving averages and the lower Bollinger band. The hourly chart confirms the broader weakness; the shorter timeframe offers only a limited counterpoint.
Summary
Key takeaways
- NeuroPace stock moved from $12.02 to $6.33 as of 14:19 ET on Friday, down 47.3% versus the previous close, with 185,317 shares traded so far.
- Daily RSI14 is 18.26, in oversold territory, and the daily MACD histogram is -0.4. Price is below the 20-session EMA at $12.15, the 50-session EMA at $13, and the 200-session EMA at $14.07.
- Hourly RSI14 is 13.63, also oversold, and price remains below the 20-hour EMA at $9.94, the 50-hour EMA at $11.45, and the 200-hour EMA at $12.67.
- Daily ATR14 increased to $1.11 from $0.69, indicating greater measured volatility than in the preceding session.
- The 15-minute MACD histogram is positive at 0.24, but the 15-minute RSI14 is 24.2 and price is below the 20-period EMA at $6.97.
On Friday, November 13, 2026, NPCE opened at $6.35, traded between a low of $5.47 and a high of $6.95, and was last at $6.33, against a previous close of $12.02. The stock was down 47.3% versus the previous close, with 185,317 shares traded so far. The session remained open.
NeuroPace stock faces a revenue and guidance setback
A report published before Friday’s open by Investing.com said NeuroPace reported third-quarter revenue of $23.1 million against forecasts of approximately $27.1 million. It also reported a reduction in the full-year revenue outlook to $91–92 million.
Meanwhile, earnings-call coverage published on Thursday described sales below management’s expectations. It said disruptions at major treatment centers and changes to the sales organization slowed procedures using the RNS System. That operating context accompanies a chart whose dominant signals remain bearish.
Daily structure sets the bearish bias
NPCE’s daily chart is bearish: price is below all three daily EMAs, RSI14 stands at 18.26, and the MACD histogram is -0.4. The 20-session EMA is at $12.15, the 50-session EMA at $13, and the 200-session EMA at $14.07. This ordering supports the bearish trend assessment rather than a bullish reading based on oversold conditions alone.
Notably, daily RSI14 at 18.26 is in oversold territory. The daily MACD line is -0.71, below its signal at -0.31. Both momentum measures therefore favor the bearish case.
Price also sits below the daily lower Bollinger band at $9.56, with the mid-band at $12.47. Meanwhile, daily ATR14 increased to $1.11 from $0.69, indicating greater measured volatility. An oversold reading does not by itself establish support.
The daily first support, S1, at $11.72 is above the current price. The daily pivot at $12.2 and first resistance, R1, at $12.49 are also above. These reference levels now stand overhead; their labels do not change their position relative to price.
Hourly confirmation, but a mixed short-term picture
The hourly chart confirms the bearish bias. Price is below the 20-hour EMA at $9.94, RSI14 is 13.63, and the MACD line remains below its signal. It also sits below the 50-hour EMA at $11.45 and the 200-hour EMA at $12.67.
Hourly RSI14 at 13.63 is also oversold, while the MACD line at -1.66 is below its signal at -0.97. However, the hourly MACD histogram increased to -0.69 from -0.75, though it remains negative. Price is above the hourly pivot at $6.14 and hourly R1 at $6.29. Those nearby positions qualify the immediate picture without overturning the bearish hourly average structure.
At the same time, the 15-minute MACD histogram is positive at 0.24. Its line at -1.04 is above its signal at -1.28, although both remain below zero. The 15-minute RSI14 is 24.2, still oversold, and price remains below the 20-period EMA at $6.97. This is a mixed timing signal, not confirmation of a bullish daily trend.
Bullish and bearish conditions
Two scenarios frame the near-term outlook. A bullish case requires clearing the 15-minute pivot at $6.36; a bearish case would be triggered by a break below 15-minute S1 at $6.22.
For the bullish scenario, price would need to clear the 15-minute pivot at $6.36. It would then need to surpass the upper Bollinger band at $6.41 and R1 at $6.44. A move back above those references would be required before the session high at $6.95 could be tested. The 15-minute EMA20 at $6.97 sits above price. Even then, the daily bearish structure would remain intact beneath its averages.
In contrast, a break below 15-minute S1 at $6.22 would undermine the local bullish case. The next references would be the hourly pivot at $6.14 and hourly S1 at $6.01. Below those levels, the session low at $5.47 would become the key downside reference.
Overall, NPCE sits between 15-minute support at $6.22 and the pivot at $6.36, while the daily chart remains bearish. Daily ATR shows increased volatility. The positive short-term MACD signal has not resolved the conflict with the broader structure. Whether price can hold nearby support and clear overhead levels remains uncertain.
FAQ
What is the current state of NeuroPace stock’s daily chart?
The daily chart is bearish. Price is below the 20-session EMA at $12.15, the 50-session EMA at $13, and the 200-session EMA at $14.07. Daily RSI14 is 18.26 and the MACD histogram is -0.4.
What are the key levels to watch for NeuroPace stock?
For the bullish scenario, price needs to clear the 15-minute pivot at $6.36 and R1 at $6.44. On the downside, a break below 15-minute S1 at $6.22 would expose the hourly pivot at $6.14 and hourly S1 at $6.01. The session low at $5.47 is the key downside reference.
Does the short-term chart offer any positive signals?
The 15-minute MACD histogram is positive at 0.24, with its line at -1.04 above its signal at -1.28. However, the 15-minute RSI14 is 24.2 and price remains below the 20-period EMA at $6.97, keeping this a mixed signal within the broader bearish structure.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.
Read also: VirTra stock jumps 56.11% intraday; RSI is overbought on three charts
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
